Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Fluticasone
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | 6α,9α-Difluoro-11β,17α-dihydroxy-16α-methyl-21-thia-21-fluoromethylpregna-1,4-dien-3,20-dione; S-(Fluoromethyl)-6α,9α-difluoro-11β,17α-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate |
Routes of administration |
Intranasal, inhaled, topical |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 0.51% (Intranasal) |
Protein binding | 91.0% |
Metabolism | Intranasal Liver (CYP3A4-mediated) |
Elimination half-life | 10 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H27F3O4S |
Molar mass | 444.51 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Fluticasone is a manufactured glucocorticoid used to treat nasal symptoms. Both the esters, fluticasone propionate (a brand name for which is Flovent) and fluticasone furoate, are also used as topical anti-inflammatories and inhaled corticosteroids, and are used much more commonly in comparison.
It is on the World Health Organization's List of Essential Medicines. In 2020, it was the 23rd most commonly prescribed medication in the United States, with more than 24 million prescriptions, although it is also sold over the counter.
See also
External links
- "Fluticasone". Drug Information Portal. U.S. National Library of Medicine.
Glucocorticoids |
|
||||
---|---|---|---|---|---|
Antiglucocorticoids |
|
||||
Synthesis modifiers | |||||
|
Decongestants and other nasal preparations (R01)
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Topical |
|
||||||||||
Systemic use: Sympathomimetics |
|||||||||||
|
GR |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Subsidiaries |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Predecessors, acquisitions |
|||||||||
Products |
|
||||||||
People |
|
||||||||
Litigation | |||||||||
Other | |||||||||